Lifitegrast, a topically administered LFA-1 antagonist, has been reported to inhibit binding between T cells and ICAM-1, thus alleviating CD4+-T-cell-mediated dry eye symptoms and was approved for use by the FDA in 2016. Here, ITGB2 is linked to dry eye syndrome.